The wet AMD program is effectively dead after two failed Phase 3 trials. All value now rests on the DME program (Phase 3 data Q4 2027). Monitor for any partnership or financing needs given the setback.
Price Chart
Executive Summary
EyePoint announced that its second Phase 3 trial (LUCIA) of DURAVYU in wet AMD failed to meet the primary endpoint of non-inferiority in BCVA versus aflibercept, following the same miss in the first Phase 3 trial (LUGANO). The company is pivoting to its DME program, with Phase 3 topline data expected in Q4 2027, but the wet AMD program is effectively derailed.
Key Facts
- LUCIA did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept.
- Key secondary endpoints were met: 38% reduction in treatment burden (nominal p<0.0001), 52% of eyes supplement-free, 71% receiving zero or one supplement up to Week 56.
- LUGANO (first Phase 3) also did not meet the primary endpoint in its full dataset.
- Phase 3 DME program (COMO and CAPRI trials) remains on track with topline data expected in Q4 2027.
- Phase 2 VERONA trial in DME met its primary endpoint with extended time to first supplemental injection.
- Over 630 patients treated across six completed clinical trials with no drug-related safety concerns.
Financial Impact
Wet AMD program failure eliminates a major market opportunity; DME program is now the sole value driver, with pivotal data 12+ months away. Stock likely to reprice significantly lower.
Risk Factors
- DME Phase 3 trials (COMO, CAPRI) may also fail to meet endpoints, wiping out pipeline value.
- Potential need for dilutive financing given the wet AMD setback and extended cash runway requirements.
- Regulatory path for DURAVYU in any indication is now uncertain.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3383257 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G | $0.3600 | awaiting T+5 | — | $0.3700 (+2.78%) |
Oct 19, 2026 8d ago | 8-K | $0.4400 $0.3657 | ▲ +16.89% | ▲ +16.74% | $0.3700 (+15.91%) |
Oct 19, 2026 8d ago | 8-K | $0.4400 $0.3707 | ▲ +15.75% | ▲ +15.61% | $0.3700 (+15.91%) |
Oct 19, 2026 8d ago | Press Release | $0.4400 $0.3657 | ▲ +16.89% | ▲ +16.74% | $0.3700 (+15.91%) |
Oct 7, 2026 20d ago | SC 13G/A | $3.32 $3.01 | ▼ −9.34% | ▼ −8.36% | $0.3700 (−88.86%) |
Sep 10, 2026 6w ago | 8-K | $4.25 $3.99 | ▼ −6.12% | ▼ −5.62% | $0.3700 (−91.29%) |
Aug 18, 2026 10w ago | Insider Buy | $6.30 $4.99 | ▼ −20.79% | ▼ −20.41% | $0.3700 (−94.13%) |
Aug 17, 2026 10w ago | 8-K | $4.87 $4.87 | · 0.00% | ▲ +1.19% | $0.3700 (−92.40%) |
Aug 5, 2026 11w ago | 8-K | $12.25 $13.53 | ▲ +10.45% | ▲ +10.10% | $0.3700 (−96.98%) |
Jul 30, 2026 12w ago | 8-K | $12.86 $12.83 | ▼ −0.23% | ▼ −3.86% | $0.3700 (−97.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers